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Abstract: The mouse model of Alzheimer’s disease (AD), Tg2576 mice (APP), has provided
valuable information, such as the role of the metallothionein (MT) family in their behavioral
and amyloidosis phenotypes. In this study, we further characterize the role of MT-1 by crossing
Mt1-overexpressing mice with Tg2576 mice (APPTgMT). In 14-month-old mice, MT-1(/2) protein
levels were dramatically increased by Mt1 overexpression throughout the cortex (Cx), which showed
a prominent caudal-rostral gradient, and the hippocampus (HC). There was a trend for MT-1(/2)
immunostaining to be increased in the areas surrounding the amyloid plaques in control male mice
but not in Mt1-overexpressing mice. Gliosis was elicited by the amyloid plaques, but the effects of
Mt1 overexpression were modest. However, in hippocampal western blots the microglial marker
Iba-1 was increased in old male APPTgMT mice compared to APP-wild type (APPWT) mice, and the
opposite was observed in young mice. Hippocampal CA1 neuronal loss was observed in Tg2576 mice,
but was unaffected by Mt1 overexpression. Aging increased Zn and Cu levels differently depending
on brain area, sex, and genotype. Thus, the effects of Mt1 overexpression on the phenotype of Tg2576
mice here studied are modest.
Keywords: Alzheimer’s disease; Tg2576; metallothionein-1; amyloid plaques; gliosis; CA1 neuronal
loss; metals
1. Introduction
Alzheimer’s disease (AD) is a devastating disease that causes a progressive loss of cognitive
functions. It is characterized by the presence of extracellular deposits of amyloid-β peptides
(amyloid plaques), intracellular deposits of hyperphosphorylated tau protein (neurofibrillary tangles),
neuroinflammation, and oxidative stress in brain areas such as the hippocampus and the cortex [1,2].
Transition metals such as Cu or Fe, together with Zn, contribute to oxidative stress as well as to the
aggregation and precipitation of amyloid-β peptides in the AD brain [3,4].
A number of studies suggest that the metallothionein (MT) family of proteins may be important for
the understanding of AD. MT-1/2 isoforms have been shown to be upregulated in AD [5–8], whereas
the results for MT-3 are less consistent [9,10]. In accordance with the human disease, MT-1/2 protein
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levels are increased in areas enriched in amyloid plaques in several AD mouse models, including the
Tg2576 mice [8,11]. Ascertaining the putative role(s) of MTs in these mouse models is of great interest.
Results obtained in transgenic mice crossing the Tg2576 mice with MT-1/2 deficient (Mt1&2 KO) mice
showed that these MT isoforms are involved in the formation of amyloid plaques, particularly in the
hippocampus [12]. This possibility has been reinforced by recent results obtained crossing the Tg2576
mice with Mt1-overexpressing (TgMT) mice [13]. Moreover, some behavioral traits were also shown to
be influenced by MT-1. Nevertheless, much remains to be understood. Here we expand the results by
analyzing MT-1/2 immunohistochemistry, gliosis, neuronal survival, and Zn and Cu levels.
2. Results
2.1. MT-1/2 Immunostaining Is Dramatically Increased in TgMT Mice
Representative MT-1/2 immunostaining in wild-type (WT) and TgMT mice (Figure 1A) as well
as quantification of this staining in the cortex of the different genotypes (Figure 1B) clearly indicates
that total MT-1/2 protein levels were dramatically increased throughout the brain in TgMT male and
female mice (p < 0.001). The antibody used for MT immunohistochemistry (IHC) recognizes both MT-1
and MT-2 isoforms; the increase in total MT-1/2 levels presumably reflects the expression of the Mt1
transgene (thus increasing MT-1 protein levels) rather than changes in MT-2 levels. Interestingly, we
noticed a prominent gradient in MT-1/2 IHC, with the highest staining in the caudal cortex and the
lowest in the frontal cortex (Figure 1B; p < 0.001). Such a gradient was present regardless of amyloid
precursor protein (APP) expression, which produced a major accumulation of Congo Red positive
dense amyloid plaques localized in the medial part of the brain but less so in the caudal and frontal
cortex (Figure 1C; p < 0.001). MT-1/2 immunostaining showed a trend for increased levels in APPWT
mice (compared to WT mice), whereas the opposite was observed in APPTgMT mice (compared to
TgMT mice) (Figure 1B). In the cortex of male mice this resulted in a significant interaction between
APP expression and Mt1 overexpression (p < 0.05), and between APP expression, Mt1 overexpression,
and area of the cortex (p < 0.05).
In the hippocampus (Figure 2A,B), MT-1/2 immunostaining was also increased in TgMT and
APPTgMT mice in both sexes relative to their respective controls (p < 0.001). As in the cortex, in the
hippocampus of male mice the interaction between these two factors (APP and Mt1 overexpression)
was significant (p < 0.05), since there was an increase of MT-1/2 protein levels in APPWT mice
compared to WT mice but not in APPTgMT mice compared to TgMT mice (Figure 2B). Double staining
with Congo Red and MT-1/2 (Figure 2A) allowed comparisons of MT-1/2 protein levels in areas
surrounding the dense amyloid plaques (Figure 2A right, arrow) to areas without plaques. As might
be expected, there was a trend for increased MT-1/2 immunostaining near amyloid plaques, but this
was significant (p < 0.05) only for male mice (Figure 2C). There were no significant differences in
this regard in the cortex (data not shown). Thus, the effect of transgenic Mt1 expression on MT-1/2
immunostaining is much more evident than changes in its association with amyloid plaques.
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Figure 1. Effect of Mt1 overexpression on MT-1/2 and Congo Red staining in the cortex. (A) 
Representative brain MT-1/2 immunostaining in wild-type (WT) (top) and TgMT (bottom) mice; (B) 
Quantification of MT-1/2 IHC of the different genotypes in the cortex showed a dramatic increase in 
Mt1-expressing (TgMT and APPTgMT) mice ( p at least ≤0.05 vs. WT or APP mice, respectively) 
with a prominent caudal-frontal gradient. As revealed by the significant interaction between APP 
expression and Mt1 overexpression (♠ p < 0.05 in male caudal region; the rest was not significant), 
APP expression tended towards an increase in MT-1/2 in WT mice; and the opposite was true in TgMT 
mice; (C) The greatest accumulation of dense amyloid plaques (stained with Congo Red) was 
localized in the medial area in both sexes. Results are mean ± SEM (n = 7–11). Scale bar: 400 µm. a.u., 
arbitrary units. 
 
Figure 2. Effect of Mt1 overexpression on MT-1/2 staining in the hippocampus. (A) Representative 
immunostaining for MT-1/2 counterstained with Congo Red in the hippocampus of APPTgMT mice 
(left); scale bar: 200 µm. A higher magnification of the black lined square area is shown at the right to 
better demonstrate plaques stained with Congo Red dye (arrow); scale bar: 50 µm; (B) Quantification 
of total MT-1/2 immunohistochemistry (IHC) produced similar results to the cortex, with dramatic 
increases in TgMT and APPTgMT mice ( p < 0.001 vs. WT or APP mice, respectively). An opposing 
trend of APP expression was again seen between WT and TgMT male mice (♠ p < 0.05 interaction); 
(C) Comparison of MT-1/2 levels associated with plaques to those not associated with plaques 
indicated an increased immunostaining in the vicinity of the amyloid plaques only in male mice ( 
p < 0.05 vs. staining associated to plaques). Results are mean ± SEM (n = 7–11). a.u., arbitrary units. 
Figure 1. Effect of Mt1 overexpression on MT-1/2 and Congo Red staining in the cortex.
(A) Representative brain MT-1/2 immunostaining in wild-type (WT) (top) and TgMT (bottom) mice;
(B) Quantification of MT-1/2 IHC of the different genotypes in the cortex showed a dramatic increase
in Mt1-expressing (TgMT and APPTgMT) mice (F p at least ≤0.05 vs. WT or APP mice, respectively)
with a prominent caudal-frontal gradient. As revealed by the significant interaction between APP
expression and Mt1 overexpression (♠ p < 0.05 in male caudal region; the rest was not significant), APP
expression tended towards an increase i MT-1/2 in WT mice; and the opposite was true in TgMT mice;
(C) The greatest accu ul tion of dense amyloid plaqu s (stained with Congo Red) was localized in the
medial are in bo h sexes. Results are mean ± SEM (n = 7–11). Scale bar: 400 µm. a.u., arbitrary units.
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increases in TgMT and APPTgMT mice ( p < 0.001 vs. WT or APP mice, respectively). An opposing 
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Figure 2. Eff ct of Mt1 overexpression on MT-1/2 staining in the hip ocampus. (A) Representative
immunostaining for MT-1/ c terstai e it ongo Red in the hippoca pus of APPTgMT mice
(left); scale bar: 200 µm. A higher agnification of the black lined square area is shown at the right to
bet er demonstrate plaques stained with Congo Red dye (ar ow); scale bar: 50 µm; (B) Quantification
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2.2. Mt1 Overexpression Has Only Minor Effects on the Gliosis Elicited by Amyloid Plaques
As expected, amyloid plaques elicited a dramatic gliosis in the hippocampus (Figure 3) and
cortex (not shown). In contrast to MT-1/2 immunostaining, both GFAP (Glial Fibrillary Acidic
Protein) (astrocytes; Figure 3A,B) and Iba-1 (Ionized calcium binding adaptor molecule 1) (microglia;
Figure 3C,D) immunostainings were significantly (p < 0.001) increased in the area surrounding Congo
Red-positive plaques compared to areas without plaques. Mt1 overexpression did not appear to
influence these immunostainings for astrogliosis and microgliosis (Figure 3B,D, respectively). Thus,
the presence or absence of amyloid plaques appeared to influence gliosis in the hippocampus more
than the expression of Mt1, at least in the tissue sections analyzed.
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Figure 3. Effect of Mt1 overexpression on gliosis in the hippocampus. (A,C) Representative 
immunostaining for GFAP (astrocytes) and Iba-1 (microglia), respectively, counterstained with Congo 
Red, in the hippocampus of APPTgMT mice (left); scale bar: 200 µm. On the right, a higher magnification 
of the black lined square area from left panel shows astroglia and microglia surrounding dense plaques; 
scale bar: 50 µm; (B,D) Quantification of GFAP and Iba-1 IHC indicated a dramatic increase in the 
vicinity of the plaques. Results are mean ± SEM (n = 11–18);  p < 0.001 vs. plaque-associated staining. 
a.u., arbitrary units. 
In contrast, results obtained by western blot using the whole hippocampus of one hemisphere 
did show small, but in some cases significant, effects of Mt1 overexpression (Figure 4A,B). Thus, in 
the hippocampus of male mice a significant (p < 0.05) increase of Iba-1 levels was observed in old 
mice; the same trend was observed in female mice. In contrast, hippocampal Iba-1 levels were 
decreased by Mt1 overexpression in young male mice (Figure 4B; p < 0.05)). GFAP levels followed a 
similar pattern. In contrast to the hippocampus, in the cortex, Mt1 overexpression did not 
significantly influence gliosis at any age as evaluated by western blot (Figure 4B). 
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In contrast, results obtained by western blot using the whole hippocampus of one hemisphere
did show small, but in some cases significant, effects of Mt1 overexpression (Figure 4A,B). Thus, in the
hippocampus of male mice a significant (p < 0.05) increase of Iba-1 levels was observed in old mice;
the same trend was observed in female mice. In contrast, hippocampal Iba-1 levels were decreased by
Mt1 overexpression in young male mice (Figure 4B; p < 0.05)). GFAP levels followed a similar pattern.
In contrast to the hippocampus, in the cortex, Mt1 overexpression did not significantly influence gliosis
at any age as evaluated by western blot (Figure 4B).
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old male mice but decreased in young males; the latter also showed decreased GFAP levels. Data are 
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2.3. t1 Overexpression Does Not Affect Hippocampal CA1 Neuronal Loss
A clear neuronal loss was observed in the CA1 hippocampal area of Tg2576 male and female mice,
with a clear thinning of the pyramidal layer as revealed by Nissl staining. This was not influenced
significantly by Mt1 overexpression (Figure 5).
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2.4. Mt1 Overexpression Has only Minor Effects on Zinc and Copper Levels
Total hippocampal and cortical homogenates from young and old mice were used to assess zinc
and copper content by ICP-MS (Figure 6). In the hippocampus, copper levels were increased by aging
(p < 0.001), a trend favored by APP expression and in both sexes. Mt1 overexpression decreased the
effect of APP expression on copper levels of young female mice. Aging had a significant decreasing
effect on zinc levels (p at least <0.05) in the hippocampus, but Mt1 overexpression did not show a
significant effect in this regard. In the cortex, both zinc and copper levels were moderately increased
by aging (p at least <0.005); this trend was opposed by APP expression (significantly in male mice), in
sharp contrast with the cortex. Mt1 overexpression tended to increase cortex zinc levels, but variability
precluded statistical significance.
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Figure 6. Effects of Mt1 overexpression on Zn and Cu levels. Total hippocampal (top) and cortical
(bottom) homogenates from young (~6 months) and old (~14 months) mice were analyzed by ICP-MS.
In the hippocampus, copper and zinc levels were increased and decreased by aging, respectively; both
metals were increased in the cortex. APP and Mt1 expression showed different effects depending on
the metal and brain area. Results are mean ± SEM (n = 7–11); N p at least ≤0.05 vs. APP negative mice.
♠ p < 0.05 interaction between APP and TgMT.
3. Discussion
We previously showed that Mt1 overexpression influenced the Tg2576 mice phenotype in a
number of ways, including the formation of amyloid plaques and so e behavioral traits [13]. It is
important to emphasize that the effects caused b t1 erex ression are consistent with those
observed in Tg2576/Mt1&2 KO mice [12]. i t , t1 overexpre sion slightly but significantly
increased the amyloid load in the hip ocampus, site trend was observed in Mt1&2
KO mice. However, the mechanisms underlyi t t f Ts on a yloid plaques and other
physiological/pathol gical variables remain to be fully determined. We herewith expand those results
by analyzing gliosis, neuronal survival, and accumulation of essential metals in the critical brain areas
for AD, cortex, and hippocampus.
Since amyloid plaques are mostly produced in the cortex and the hippocampus, we focused our
analysis in these brain areas. We previously showed that Mt1 (but not Mt3) mRNA levels measured by
Int. J. Mol. Sci. 2017, 18, 251 7 of 12
in situ hybridization were clearly increased in TgMT mice [13,14]. Since the antibody used recognizes
both MT-1 and MT-2 isoforms, it was expected that MT-1/2 immunostaining would also be clearly
increased, and indeed that was the case in both male and female mice. Interestingly, a caudal-frontal
gradient in MT-1/2 IHC was observed in the cortex. It is likely that such a gradient could be related to
the prominent expression of MT-1/2 in astrocytes [15–17], since these cells tend to show that type of
gradient when expressing GFAP [18,19].
The caudal-frontal gradient in the MT-1/2 IHC was present regardless of the APP expression,
although certainly some interesting trends could be observed. Thus, when comparing WT and APPWT
mice, MT-1/2 immunostaining tended to increase in the latter, presumably because of the amyloid
plaques and the associated neuroinflammation. This is in accordance with previous results with in
situ hybridization, which indicated that Mt1 mRNA levels were increased in cells surrounding the
amyloid plaques [13,20]. The fact that the Tg2576 mouse model is an AD model with a relative paucity
of amyloid plaques, added to the high basal expression of MT-1/2, makes it difficult to see prominent
increases of these proteins, which nevertheless we observed, albeit only significantly in male mice.
In contrast, when comparing TgMT and APPTgMT mice, MT-1/2 immunostaining tended to decrease
in the latter. The very same pattern was observed in the hippocampus. The reason for these opposing
trends remains to be established. They might be related to differences between the regulation of
the normal (endogenous) MT-1/2 genes and that of the minimally marked Mt1 (transgenic) gene.
According to Palmiter et al. [21], the minimally marked Mt1 gene, while being expressed about 50%
less on a per gene basis, shows a normal tissue distribution, and responds normally to factors such
as heavy metals, dexamethasone, and lipopolysaccharide (LPS), which in principle strongly suggests
that the transgene is regulated in a similar fashion to the endogenous Mt1 gene. Therefore, MT-1/2
immunostaining should also be increased by the amyloid plaques in the APPTgMT mice, but this did
not occur. Thus, other reasons may be involved, perhaps specifically related to the amyloid plaques
(rather than a general phenomenon such as stress) which deserves further attention.
Other putative mechanisms set in motion by Mt1 overexpression could be related to altered gliosis
and neuroinflammation and/or a modulation in normal metal ion homeostasis. MT-1/2 proteins have
been shown to affect gliosis in a number of ways [14,16,17,22]. Astrocytes surrounding the amyloid
plaques in old mice were more reactive as revealed by prominent GFAP immunostaining compared to
areas without plaques, but, in accordance with our previous study using Mt1&2 KO mice [12], Mt1
overexpression did not significantly affect GFAP levels in either the hippocampus or cortex. Similarly,
microgliosis, assessed with Iba-1 immunostaining, was not altered significantly by Mt1 overexpression
in the tissue sections of cortex and hippocampus that were analyzed. In contrast, results obtained
by western blot using the whole hippocampus (and thus more representative compared to sampled
sections) of one hemisphere of old male mice showed an increase of Iba-1 levels; the same trend was
observed in female mice. This is consistent with the western blot results found in Mt1&2 KO mice [12].
It is likely that this effect of Mt1 overexpression is related to the increased amyloid plaque burden
these mice show in the hippocampus [13]; in accordance, Mt1&2 KO mice show decreased amyloid
burden [12]. Thus, through an unknown mechanism, MT-1/2 seem to control the amyloid plaque
deposition, which, in turn, drives microglial reactivity.
The situation is different at five months of age, since no amyloid plaques are yet present [23,24].
In contrast to the results found in old mice, Mt1 overexpression significantly decreased both
microgliosis and astrogliosis in the hippocampus; the same trend was present in the cortex. Remarkably,
this was occurring again only in male mice. Moreover, the results are generally consistent with those
found in Mt1&2 KO mice [12]. An inhibitory effect of MT-1/2 on microglia has also been suggested
in other studies [25–27]. Altogether, the present results suggest that while MT-1 may have a direct
inhibitory role controlling microglia, it is overridden by an indirect stimulatory role in the case of APP
positive mice because of its effects on the formation of amyloid plaques.
In old APP positive (APPWT and APPTgMT) mice, we readily observed neuronal loss of
hippocampal CA1 neurons, a known hallmark of mice carrying the “Swedish mutation” [28];
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interestingly, this is also observed in AD patients [29]. In this context, it was somewhat surprising
that Mt1 overexpression did not significantly influence neuronal survival [30–32]. Whether or not this
is related to different neuronal susceptibilities, to MT-1 levels, or to the specific experimental model
causing neurodegeneration remains to be established.
On the other hand, MTs are Zn, Cu-binding proteins [9], metals which have been reported to
participate in amyloid-β peptide aggregation [33] and in ROS production [34]. As expected [12], aging,
APP and Mt1 overexpression affected metal content in a modest way. Yet, these were remarkable
effects. Aging had different effects on Zn and Cu accumulation in the cortex and the hippocampus.
Thus, in the cortex aging increased Zn (slightly) and Cu levels (more robustly), and this effect of
aging was partially blunted in APP positive mice, which is consistent with previous studies [12,35].
In contrast, in the hippocampus, aging increased Cu levels but decreased Zn levels, and both Zn and
Cu levels were increased by APP expression. These results highlight the importance of measuring
metals in specific areas of the brain rather than bulk brains. Interestingly, increased copper and iron
levels with aging have been proposed as a mechanism to explain the age-dependent onset of amyloid
neuropathology in the same mice (Tg2576) [35], more so considering hippocampal neuropathology,
where APP positive mice had an even higher accumulation of Cu with aging. Mt1 overexpression
only caused minor effects on metal levels, and thus they are unlikely to underlie the phenotype of
APPTgMT mice in comparison to APPWT mice (see [12] for further discussion). It should be noted
that we have measured total Zn and Cu levels, and therefore we cannot rule out specific effects of MT-1
on free metal ion levels and/or bound metal levels.
In summary, the present study evidences that while MT-1/2 are able to modulate the formation of
amyloid plaques and some behavioral traits [12,13], MT-1 shows modest effects on glial activation,
neuronal survival, and heavy metal accumulation.
4. Materials and Methods
4.1. Animals
The parental strains used in this study were C57BL/6JOlaHsd as a wild-type (WT) strain
(Harlan, KY, USA), TgMT mice, which carry 56 copies of a minimally marked Mt1 (Mt1*) gene [21]
(B6.Cg-Tg(Mt1)174Bri/J; The Jackson Laboratory, Bar Harbor, ME, USA), and the AD mouse model
Tg2576 which expresses the human APP695 harboring the Swedish K670N/M671L mutations under
the control of the hamster prion protein promoter [23] (Taconic Europe A/S; Ry, Denmark). These
strains were crossed and genotyped as previously described [13] to produce WT, TgMT, APPWT (APP
in Figures), and APPTgMT mice. Throughout the manuscript, we may refer the two former groups as
APP negative mice, and the two latter as APP positive mice. Mice were killed at ~6 and ~14 months
of age.
Mice were housed in groups and given ad libitum access to food and water in a 12-h dark-light
cycle under constant temperature (~22 ◦C). Animals were killed by decapitation and the brain quickly
removed on placed ice. The cortex (Cx) and hippocampus (HC) of the right hemisphere were quickly
dissected, frozen with liquid nitrogen, and stored at −80 ◦C. The left hemisphere was fixed by
immersion in 4% paraformaldehyde and stored in 70% ethanol at 4 ◦C until further processing for
paraffin-embedding. All experimental procedures were approved by the Ethics Committee in Human
and Animal experimentation from the Autonomous University of Barcelona (CEEAH2996, 29 May
2015) and Servei de Biodiversitat i Protecció dels Animals (8837, 15 December 2015).
4.2. Immunohistochemistry (IHC) and Histochemistry (HC)
Fixed brains were paraffin-embedded and cut sagitally in 8 µm-thick sections for assessing
MT-1/2 (primary antibody: anti-MT 1/100, DAKO, M0639, Clone 9; secondary antibody: biotinylated
anti-mouse IgG 1:300, SIGMA, St. Louis, MO, USA), astrogliosis (primary antibody: anti-GFAP
1:900, DakoCytomation, Glostrup, Denmark A/S; secondary antibody: biotinylated anti-rabbit IgG
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1:300, Vector Laboratories, Inc., Burlingame, CA, USA), and microgliosis (primary antibody: anti-Iba1
1:1500, WAKO, Tokyo, Japan; secondary antibody: biotininylated anti-rabbit IgG (H + L) 1:300, Vector
Laboratories, Burlingame, CA, USA) as described [12].
All IHC performed were double-stained with Congo red stain (SIGMA) to identify areas with
dense plaques with a congophilic core, in order to assess the MT-1/2 IHC and the activation of
astrocytes and microglia surrounding the plaques compared to areas without plaques.
In order to quantify hippocampal CA1 neurons, 0.1% of Cresyl Violet (SIGMA) was used to stain
Nissl substance. An image of CA1 of the hippocampus was acquired using a bright field microscope
(Nikon Eclipse E400, Nikon Corporation, Tokyo, Japan). The images were analyzed using Image J
software (1.49 v) [36] and the average of three measures of CA1 thickness was taken. Analyses were
performed on two non-consecutive sections per mouse.
Stained sections were examined with a bright-field microscope (Nikon Eclipse 90i, Nikon
Corporation) and images were acquired from the cortex and the hippocampus using a Nikon digital
camera DXM 1200F and Nikon Act-1 v. 2.70 software. The images were analyzed using Image J
software. A limited area was determined around the dense plaques stained with Congo red and the
ImageJ color deconvolution plugin by Gabriel Landini [37] was used in order to separate the DAB and
Congo red colors, obtaining afterwards the quantity of immunostaining associated to dense plaques,
the quantity not associated and the total amount of staining of the brain areas studied (Cx and HC).
The quantitation of immunostaining in the cortex was divided in three regions: caudal, medial (~above
hippocampus) and frontal.
Histological analyses were performed on at least three non-consecutive sections per mouse.
4.3. Western Blotting
Total homogenates of Cx and HC were obtained by sonication in 50 mM Tris-HCl (pH 7.6), 0.01%
NP-40, 150 mM NaCl, 2 mM EDTA, 3% sodium dodecyl sulfate (SDS), 1mM phenylmethylsulfonyl
fluoride (PMSF), 1% sodium deoxycholate and protease inhibitor cocktail (Sigma-Aldrich, Madrid,
Spain). Protein concentration was measured using the bicinchoninic acid (BCA) protein assay as
specified by the manufacturer (Pierce, Thermo Fisher Scientific Inc; Rockford, IL, USA) and samples
were stored at −80 ◦C until they were used. Western blot for astrocytosis (anti-Glial Fibrillary Acidic
Protein –GFAP– 1:40,000, DakoCytomation, Denmark A/S) and microgliosis (anti-ionized calcium
binding adaptor molecule 1 –Iba-1– 1:3000, Wako Pure Chemical industries, Osaka, Japan) was carried
out as previously described [12]. Membranes were developed with ECL reagent (Amersham, GE
Healthcare, Buckinghamshire, UK) and exposed to autoradiographic film (Kodak, Rochester, NY, USA);
for quantification, images were acquired and quantified using the Bio-Rad laboratories (Hercules, CA,
USA) QuantityOne ChemiDoc software (version 4.6.3).
4.4. Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
Cortical and hippocampal tissues were prepared as described above. Following digestion of the
samples with HNO3 at 60 ◦C, and dilution in 1% HNO3, determination of Zn and Cu was carried out
as described [12].
4.5. Statistical Analysis
Data was analyzed using the Statistical Package for Social Sciences (SPSS) version 17.0. Males and
females were analyzed separately. The data was analyzed using Generalized Linear Model (GLZ) using
APP (APP positive vs. APP negative) and Mt1 overexpression (TgMT positive vs. TgMT negative) as
main factors. In the IHC, when the intensity around the plaques was compared with the non-associated
intensity, “association to plaques” was used as grouping factor; and when several areas of the cortex
were studied, this was an additional factor. In the study of the metal content in the hippocampus “age”
was used as a factor (young and old). Statistical significance was defined as p ≤ 0.05.
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